Compared to the global trends, the development of new modality drugs has a low probability of success and requires thorough analysis and strategy from the development stage. In order for Korea to become a global leader in biohealth, it must be competitive in the field of new modality research and development, and partnerships such as cooperation with Big Pharma are necessary due to the enormous research and development costs required. Accordingly, we aim to lay the basis for global cooperation by introducing domestic and international trends in new modality medicines and showcasing excellent domestic technologies.